Search
Search
Reliable diploid cell growth supports consistent vaccine production. Gibco diploid cell media are designed to maintain healthy attachment and viability across diploid lines such as MRC-5, WI-38, KMB17, and chicken embryo fibroblasts (CEF). As you move from serum-based to reduced-serum or animal origin–free (AOF) workflows, these formulations help reduce process risk and support easy adaptation from development to large-scale cGMP production.
Gibco diploid cell media facilitate consistent performance across vaccine development and production. Each serum-reduced, chemically defined, and animal origin–free formulation supports workflow efficiency, process control, and reproducibility.
Some benefits include:
Efficient workflows are critical for consistent viral vaccine production. Diploid cell media are designed to help simplify preparation and reduce process variability while supporting reliable growth and virus expression. Serum-reduced and animal origin–free formulations allow for smooth adaptation across development and manufacturing, helping minimize the need for extensive process changes. By maintaining high cell viability and predictable virus yield, these media can accelerate production timelines and strengthen regulatory confidence across cGMP environments.
Thermo Fisher Scientific offers Gibco cell culture media that enable consistent performance across applications beyond diploid systems. Available in liquid, dry powder, and Advanced Granulation Technology (AGT) formats, these media seek to simplify preparation and help maintain reproducibility across sites.
Diploid cell lines such as MRC-5 and WI-38 are used in viral vaccine production because they retain standard chromosome structure and consistent growth. Their similarity to primary human cells supports efficient virus replication and reliable yield. Over decades of use, these cells have shown strong safety records and are well accepted by regulators for vaccine manufacturing.
Serum-based media can introduce challenges, such as variability, that can affect reproducibility and viral yield. Lot-to-lot differences alter nutrient composition, which can change cell behavior and virus expression. Serum can also increase contamination risk and complicate documentation for regulatory submission.
Serum-reduced and AOF diploid media can help improve process consistency by reducing undefined serum components that cause variability. With defined formulations, cells can receive uniform nutrients at every stage, supporting reproducible growth and virus yield. These media also lower contamination risk and simplify qualification, helping maintain consistent performance across cGMP manufacturing sites.
Gibco diploid cell medium is designed for use in cGMP manufacturing environments. Its defined compositions support traceability, documentation, and lot-to-lot consistency needed for regulated vaccine production. These attributes help manufacturers maintain quality control and reproducibility across global sites.
For research use or further manufacturing. Not for diagnostic use or direct administration into humans or animals.